EDX Medical Group has positioned its AIM admission alongside a broader push to commercialise highly accurate diagnostic tests across cancer and other major disease areas, with prostate cancer detection emerging as a near-term focus for clinical validation, public relevance and commercial positioning.
The company is developing diagnostic products designed to improve the accuracy and usefulness of early disease detection. Its work is centred primarily on cancer, while also extending into cardiovascular and infectious disease testing. The strategy is to build tests that can be used across hospitals, private healthcare, the NHS, GP surgeries, pharmacies and, over time, home settings. Diagnostic adoption often depends not only on clinical performance, but also on how easily tests can be placed into existing healthcare workflows.
A key current programme is the Scottish prostate cancer testing initiative, which is planned to involve 25,000 men across multiple centres. The programme is designed to examine biomarkers from blood, saliva and urine samples, generating a large evidence base to support validation of EDX Medical’s prostate testing approach. The company has said the programme is already progressing at pace, with more than 12,000 men tested within the first few months.
The prostate testing work is important because the current debate around PSA screening remains focused on accuracy, overdiagnosis and the ability to distinguish between aggressive and non-aggressive disease. EDX Medical’s approach includes PSA alongside additional biomarkers, with the aim of assessing whether a man is likely to have prostate cancer before entering an MRI pathway. The company is also seeking to help characterise the likely nature of the disease, which could support better triage and more appropriate clinical decisions.
The Scottish programme gives EDX Medical access to large-scale, real-world data at a time when demand for better cancer detection remains high. The company has said that men with no symptoms have been identified through the programme, including cases requiring further investigation through MRI and biopsy.
EDX Medical expects to release results from the prostate cancer programme later this year. The company is also moving from a research and development phase towards wider commercialisation. Its pipeline includes a bowel cancer test package combining DNA markers, faecal blood markers and genetic risk elements, as well as work in ovarian, lung and breast cancer.
Some products are already being used in hospitals, while others are moving through clinical trials and registration pathways, including MHRA registration and eventual IVDR registration in Europe. The company has described 2026 and 2027 as important years for commercial rollout, with marketing, distribution and partnerships expected to become increasingly central to execution.
EDX Medical Group plc (LON:EDX) is a UK-based listed company focused on the development of diagnostic tests that enable personalised treatment for cancer, cardiovascular and infectious diseases.
